Journal
PHYTOMEDICINE
Volume 17, Issue 3-4, Pages 170-177Publisher
ELSEVIER GMBH, URBAN & FISCHER VERLAG
DOI: 10.1016/j.phymed.2009.12.004
Keywords
Saikokaryukotsuboreito; Osteoporosis; IL-6; Herbal medicine
Categories
Funding
- Ministry of Education, Science, Sports and Culture, Japan [19791029]
- Grants-in-Aid for Scientific Research [19791029] Funding Source: KAKEN
Ask authors/readers for more resources
Purpose: Saikokaryukotsuboreito (SRB) is a traditional Japanese herbal medicine that has been used to treat hyperlipidemia. As some studies have shown that lipid-lowering drugs reduce osteoporosis, we investigated the effect of SRB on bone metabolism in the postmenopausal period using an ovariectomized (OVX) murine model. Material and Methods: Fifteen aged 9 weeks female mice were divided into three groups (n = 5 each). The OVX group and SRB group underwent bilateral ovariectomy, after which the OVX group was fed a normal diet and the SRB group fed a normal diet containing 2% SRB. The sham group underwent sham surgery and was then fed a normal diet. Eight weeks after surgery, all mice were sacrificed, and bone volume, bone histomorphometric parameters, and bone-associated phenotype were compared among the groups. Results: Compared with the OVX group, the SRB group showed suppression of bone volume loss at the tibia (SRB group: 12.7 +/- 0.7%, OVX group: 9.8 +/- 0.4%; p = 0.005, ANOVA) and lumbar spine (SRB group: 15.1 +/- 0.9%, OVX group: 11.3 +/- 0.1%; p = 0.031, ANOVA). A significant decrease in eroded surface was also observed in SRB-treated ovariectomized mice compared with the OVX group (p = 0.022, ANOVA). We also found that serum levels of interleukin (IL)-6, a primary mediator of bone resorption, in the SRB group were significantly lower than in the OVX group (SRB: 52.5 +/- 6.8 pg/ml; OVX: 138.0 +/- 23.1 pg/ml; p = 0.011, ANOVA). However, unexpectedly, SRB did not affect estradiol and total cholesterol in ovariectomized mice. Conclusion: SRB can prevent loss of bone volume and suppress serum IL-6 levels in this postmenopausal model and is a promising candidate for treatment of postmenopausal osteoporosis. (C) 2010 Elsevier GmbH. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available